884510-87-6Relevant articles and documents
TREATMENT OF METABOLIC SYNDROME WITH CYCLIC AMIDES
-
Page/Page column 56; 60, (2010/11/04)
The present application relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables are'as defined in the claims. The present application also relates to the treatment of metabolic syndrome or disorders associated with metabolic syndrome in an affected mammal by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof.
Design and optimization of renin inhibitors: Orally bioavailable alkyl amines
Tice, Colin M.,Xu, Zhenrong,Yuan, Jing,Simpson, Robert D.,Cacatian, Salvacion T.,Flaherty, Patrick T.,Zhao, Wei,Guo, Joan,Ishchenko, Alexey,Singh, Suresh B.,Wu, Zhongren,Scott, Boyd B.,Bukhtiyarov, Yuri,Berbaum, Jennifer,Mason, Jennifer,Panemangalore, Reshma,Cappiello, Maria Grazia,Mueller, Dominik,Harrison, Richard K.,McGeehan, Gerard M.,Dillard, Lawrence W.,Baldwin, John J.,Claremon, David A.
scheme or table, p. 3541 - 3545 (2010/03/31)
Structure-based drug design led to the identification of a novel class of potent, low MW alkylamine renin inhibitors. Oral administration of lead compound 21l, with MW of 508 and IC50 of 0.47 nM, caused a sustained reduction in mean arterial bl
DIAMINOPROPANOL RENIN INHIBITORS
-
Page/Page column 82-83, (2008/06/13)
Described are diaminopropanols of which are orally active and bind to renin to inhibit its activity. They are useful in the treatment or amelioration of diseases associated with elevated levels of renin activity or in the treatment of aspartic protease me